Risk of New‐Onset Myasthenia Gravis Following COVID ‐19 Infection and Vaccination: A Population‐Based Case–Control Study

Documenti analoghi

• Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients‐A Population‐Based, Matched Case–Control Study
  di: Keshet Pardo, et al.
  Pubblicazione: (2026)
• Rituximab in New‐Onset Generalized Myasthenia Gravis: Long‐Term Follow‐Up of the RINOMAX Clinical Trial
  di: Jing Wu, et al.
  Pubblicazione: (2025)
• Effects of Thymectomy in Late‐Onset Myasthenia Gravis: A Multi‐Center Longitudinal Retrospective Study
  di: Jiaxin Chen, et al.
  Pubblicazione: (2025)
• MuSK‐Myasthenia Gravis and Cancer
  di: Shigeaki Suzuki, et al.
  Pubblicazione: (2024)
• A Distinct Immunological Signature in Late‐Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study
  di: Bhaskar Roy, et al.
  Pubblicazione: (2025)